Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
Pharmacology, Toxicology and Pharmaceutical Science
3
7%
Nursing and Health Professions
2
5%
Immunology and Microbiology
1
2%
Economics, Econometrics and Finance
1
2%
Other
3
7%
Unknown
25
58%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 March 2021.
All research outputs
#29,242,848
of 32,403,885 outputs
Outputs from Investigational New Drugs
#1,405
of 1,598 outputs
Outputs of similar age
#410,227
of 470,634 outputs
Outputs of similar age from Investigational New Drugs
#20
of 30 outputs
Altmetric has tracked 32,403,885 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,598 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 470,634 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
